Form 4 for ANGO ANGIODYNAMICS INC
Accepted 2021-08-17 00:00:00 ET · period of report 2021-08-12 · accession 0001567619-21-015950 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-17 | 2021-08-12 | ANGO | Campbell Chad Thomas | SVP, GM, Vascular Access | M - OptEx | $0.00 | +2,395 | 29.1K | +9% | $0 |
| D | 2021-08-17 | 2021-08-12 | ANGO | Campbell Chad Thomas | SVP, GM, Vascular Access | F - Tax | $27.29 | -702 | 28.4K | -2% | -$19.2K |
| D | 2021-08-17 | 2021-08-12 | ANGO | Campbell Chad Thomas | SVP, GM, Vascular Access | M - OptEx | $0.00 | -6,195 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-12 | M | A | 2,395 | $0.00 | 29,056 | D | — | — | (F1) This acquisition of 2,395 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019. |
| 2 | Common | Common Stock | 2021-08-12 | F | D | 702 | $27.29 | 28,354 | D | — | — | (F2) The exempt disposition of 702 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019. |
| 3 | Derivative | Performance Right | 2021-08-12 | M | D | 6,195 | $0.00 | 0 | D | — · — to — | 6,195 Common Stock | (F3) On October 16, 2019, the reporting person received a target grant of 6,195 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited. |